GlassScriptPhysician profile
David Denenholz
NPI 1801837331
$6,450.07
in general payments reported to CMS, 2019-2025
31 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $588 · 2021: $1,263 · 2022: $991 · 2023: $1,151 · 2024: $680 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,494.58 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,444.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $402.76 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $354.58 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $349.39 | 2021-2025 | Ilumya, Blu-U |
| Novartis Pharmaceuticals Corporation | $213.03 | 2019-2025 | |
| Lilly USA, LLC | $205.14 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Pfizer INC. | $201.95 | 2019-2024 | |
| Janssen Biotech, INC. | $199.58 | 2021-2025 | Tremfya, Remicade, Stelara |
| Galderma Laboratories, L.P. | $188.90 | 2020-2025 | Nemluvio, Aklief |
| Biofrontera INC. | $164.04 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $147.56 | 2021-2025 | Opzelura |
| Organogenesis INC. | $145.55 | 2024-2025 | Cygnus Dual, Affinity |
| Allergan, INC. | $136.46 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $89.53 | 2019-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $77.32 | 2019 | |
| Revance Therapeutics, INC. | $68.46 | 2024 | Daxxify |
| Almirall LLC | $66.27 | 2021-2022 | |
| Amgen INC. | $66.27 | 2019-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $61.21 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.23 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Ucb, INC. | $55.12 | 2021 | |
| Genentech USA, INC. | $43.14 | 2021-2022 | |
| Epi Health, LLC | $38.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.84 | 2019 | |
| Dermavant Sciences, INC. | $33.69 | 2022 | |
| Journey Medical Corporation | $27.62 | 2023 | |
| Taro Pharmaceuticals USA, INC. | $24.79 | 2019 | |
| Misonix INC | $22.91 | 2021 | |
| Botanix Sb INC | $21.28 | 2025 | Sofdra |
| Mission Pharmacal Company | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Denenholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.